ROLE OF DUTPASE EXPRESSION IN CANCER CHEMOTHERAPY

DuTPase 表达在癌症化疗中的作用

基本信息

项目摘要

For more than forty years, thymidylate metabolism has been an important biochemical target for widely utilized anti-cancer agents. Inhibitors of this pathway such as the fluoropyrimidines and antifolates induce a severe depletion of TTP pools resulting in nucleotide pool imbalance and cell killing through a process termed "thymineless death." Investigation of the underlying mechanisms of this process suggest that aberrant uracil-DNA metabolism may be an important mediator of DNA damage and cell killing. The broad, long-term objectives of this proposal are: 1) to elucidate the role of aberrant dUTP metabolism as a molecular mechanism of cell killing induced by chemotherapeutic agents that target thymidylate biosynthesis and; 2) to better understand the role of key enzymes involved in dUTP metabolism in modulating chemosensitivity. In this study, the applicants propose a mechanistic analysis of thymineless death using human colon cancer cell lines that over express the enzyme deoxyuridine triphosphate nucleotide hydrolase (dUTPase). dUTPase catalyzes the hydrolysis of dUTP to form dUMP and PPi, thereby eliminating dUTP from the DNA biosynthetic pathway. The applicants hypothesize that dUTPase over-expression counters the cytotoxic effect of FUdR treatment by limiting the expansion of dUTP pools. Although there is significant evidence suggesting that uracil-DNA metabolism may be a critical factor in mediating cytotoxicity, there have been no biochemical studies performed to clarify the role of human dUTPase isoform expression in modulating chemosensitivity. The proposed studies are designed to correlate key mechanistic hallmarks of uracil-DNA mediated cytotoxicity with cell death induced by fluorodeoxyuridine. Specific Aim 1 investigates the role of dUTPase isoform over-expression as a mechanism of resistance to FUdR-induced cytotoxicity. Specific Aim 2 investigates the correlation between biochemical endpoints of aberrant uracil-DNA metabolism and chemosensitivity to FUdR. Specific Aim 3 investigates the significance of dUTPase isoform expression in predicting patient response to fluoropyrimidine-based chemotherapy and overall survival in metastatic colon cancer. A better understanding of the role of aberrant uracil-DNA metabolism in mediating thymineless death should not only enhance our knowledge of the molecular mechanism of drug action of these important chemotherapeutics, but also provide insight into novel and improved treatment strategies.
四十多年来,胸苷酸代谢一直是研究的热点

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT D LADNER其他文献

ROBERT D LADNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT D LADNER', 18)}}的其他基金

dUTPase as a Target for Drug Discovery
dUTPase 作为药物发现的靶点
  • 批准号:
    6717322
  • 财政年份:
    2004
  • 资助金额:
    $ 26.53万
  • 项目类别:
dUTPase as a Target for Drug Discovery
dUTPase 作为药物发现的靶点
  • 批准号:
    7026887
  • 财政年份:
    2004
  • 资助金额:
    $ 26.53万
  • 项目类别:
dUTPase as a Target for Drug Discovery
dUTPase 作为药物发现的靶点
  • 批准号:
    6879695
  • 财政年份:
    2004
  • 资助金额:
    $ 26.53万
  • 项目类别:
dUTPase As A Prognostic Marker in Colon Cancer
dUTPase 作为结肠癌的预后标志物
  • 批准号:
    6418699
  • 财政年份:
    2002
  • 资助金额:
    $ 26.53万
  • 项目类别:
dUTPase As A Prognostic Marker in Colon Cancer
dUTPase 作为结肠癌的预后标志物
  • 批准号:
    6620544
  • 财政年份:
    2002
  • 资助金额:
    $ 26.53万
  • 项目类别:
ROLE OF DUTPASE EXPRESSION IN CANCER CHEMOTHERAPY
DuTPase 表达在癌症化疗中的作用
  • 批准号:
    6626718
  • 财政年份:
    2001
  • 资助金额:
    $ 26.53万
  • 项目类别:
ROLE OF DUTPASE EXPRESSION IN CANCER CHEMOTHERAPY
DuTPase 表达在癌症化疗中的作用
  • 批准号:
    6489326
  • 财政年份:
    2001
  • 资助金额:
    $ 26.53万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 26.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 26.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 26.53万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 26.53万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 26.53万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 26.53万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 26.53万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 26.53万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 26.53万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 26.53万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了